API Olmesartan Medoxomil Powder
CAS.NO:144689-63-4
structural formula:C29H30N6O6
EINECS.no:604-433-1
Other names:Olmesartan Medoxomil;OlMesartan MedoxoMil SynoyM;OMST;Olmesartan MedoxomiI;Olmesartan Medoxomi;Olmesartan Medoxomi;CS-866;Olmesartan;Oralolmesartan medoxomil
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted API Olmesartan Medoxomil Powder Manufacturer & Supplier
Olmesartan medoxomil is a selective angiotensin II receptor antagonist of AT1 subtype. CS-866 is a commonly used antihypertensive drug in clinic, and its API Olmesartan Medoxomil Powder is provided by Xi'an Faithful BioTech Co., Ltd. The product is not metabolized by liver cytochrome P450 system, and has no effect on P450 enzyme, so there are no problems related to enzyme inhibition, induction or metabolism in drug interaction, and it has better safety and drug compatibility.
API Olmesartan Medoxomil Powder Introduction
We know that under the catalysis of angiotensin-converting enzyme (ACE, kinase II), angiotensin I (AT Ⅰ) is converted into angiotensin II (AT Ⅱ). Angiotensin II is the main vasopressin factor in the renin-angiotensin system, which functions by constricting blood vessels, promoting the synthesis and release of ALDOSTERONE, stimulating the heart, and facilitating the reabsorption of sodium by the kidneys. And API Olmesartan Medoxomil Powder is a prodrug, a selective angiotensin II type 1 receptor (AT1) antagonist, which can be absorbed and hydrolyzed into olmesartan through the gastrointestinal tract. Research has shown that its affinity for AT1 is more than 12500 times greater than its affinity for AT2.
Specifications
Item | Specifications | Results |
Appearance | White needle crystal powder | Confirmed |
Smell | Bitterness (small taste) | Confirmed |
Identification | 304nm-260nm. | Confirmed |
Melting Point | 248-250 °C(lit.) | Confirmed |
Sieve analysis | ≤30μm | Confirmed |
Solubility | alcohol: 20 mg/mL | Confirmed |
Water solubility | soluble | Confirmed |
Specific Rotation | +124°~ +129° | +127.1° |
(HPLC) Related substances | (1)(Single):≤0.5%；(2)(Total):≤1.0% | 0.31%；0.59% |
Loss On Drying | ≤0.5% | 0.1% |
Assay | ≥98.5% | 99.5% |
| Conclusion | Conform with enterprise specification （USP 41）. |
Why Choose Us?
The olmesartan medoxomil we provide has the advantages of long-lasting stability, potent blood pressure lowering, and good tolerability. Can maintain stable blood pressure control for 24 hours, avoid significant fluctuations in blood pressure, and reduce damage to target organs. In addition, it also has the effect of reducing urinary protein. It has a good effect on patients with arteriosclerosis, myocardial hypertrophy, heart failure, diabetes and kidney disease, and has a certain protective effect on cerebrovascular, cardiovascular and kidney diseases. If you are interested, please leave a message via email: sales8@faithfulbio.com ,Welcome to the store for inquiries.
Different mechanisms:
CS-866 selectively blocks the binding of angiotensin II to vascular smooth muscle AT1 receptors, thereby inhibiting the vasoconstrictive effect of angiotensin II. Therefore, its function is independent of the AT Ⅱ synthesis pathway. Research has shown that blocking the renin-angiotensin system (RAS) using ACE inhibitors is a mechanism of many drugs for treating hypertension. However, ACE inhibitors also inhibit the degradation of bradykinin, while olmesartan medoxomil does not inhibit ACE, so it does not affect bradykinin. Its main function is to block the angiotensin II receptor and inhibit the negative feedback regulation mechanism of angiotensin II on renin secretion. And the resulting increase in plasma renin activity and circulating angiotensin II concentration does not affect its antihypertensive effect.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1: What are the common adverse reactions?
The adverse reactions of olmesartan medoxomil are usually mild and transient. In placebo-controlled clinical trials, the only adverse event with an incidence rate greater than 1% and higher than the placebo treatment group was dizziness (3% vs. 1%). Adverse events with an incidence rate similar to the placebo group and greater than 1% include back pain, bronchitis, elevated creatine kinase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza like symptoms, pharyngitis, rhinitis, and sinusitis.
Q2: What are the serious adverse reactions?
Rare but serious adverse reactions include angioedema, rhabdomyolysis, acute kidney failure, elevated blood creatinine, etc. Adverse reactions reported after listing also include allergic reactions, hyperkalemia, hair loss, urticaria, etc. Laboratory tests occasionally show a slight decrease in hemoglobin and hematocrit, an increase in liver enzymes, and/or an increase in blood bilirubin, but they usually return to normal on their own.
Q3: How is it stored correctly?
It should be stored in a dark, sealed place, in a cool and dry place, away from direct sunlight and humid environments. The ideal storage temperature is between 15 ° C and 30 ° C, avoiding high or low temperature environments. It should be stored out of reach of children and kept in its original packaging intact.
Q4: What is its shelf life?
The shelf life of API Olmesartan Medoxomil Powder is usually 24-36 months, and the specific shelf life may be affected by storage conditions, packaging integrity, production batch, and other factors. Expired drugs should not be continued to be used and should be disposed of properly in accordance with local drug management regulations.
Contact us
Our olmesartan medoxomil raw powder was selected on the basis of its high quality assurance system certified by FDA/EDQM, strict GMP production standards, excellent quality stability with purity over 99.5% and impurity control ≤ 0.5%, as well as the competitive price advantage based on large-scale production, and a complete solution with full-cycle technical support and supply chain guarantee. Interested, please leave a message, Our email address is:sales8@faithfulbio.com).
